Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2017

Ho Chao-Chi, Liao Wei-Yu, Lin Chih-An, Shih Jin-Yuan, Yu Chong-Jen, Yang James Chih-Hsin

Abstract excerpt

INTRODUCTION: AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used. Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified. It is unclear, however, whether the bypass pathway is also a mechanism of resistance in patients after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Bone Neoplasms

Share to Neoplasm Staging

Share to Piperazines

Share to Pleural Effusion, Malignant

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 27923714
DOI: 10.1016/j.jtho.2016.11.2231

Genes

BRAF
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.PMID 27923714Read ↗

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?Semantic proximity Read ↗

Acquired resistance mechanisms to osimertinib: The constant battle.Semantic proximity Read ↗

Mechanisms of resistance to osimertinibSemantic proximity Read ↗

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer.Semantic proximity Read ↗

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.Semantic proximity Read ↗

Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.Semantic proximity Read ↗

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Mechanisms of osimertinib resistance and emerging treatment options.Semantic proximity Read ↗

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.Semantic proximity Read ↗

Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case reportSemantic proximity Read ↗

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to OsimertinibSemantic proximity Read ↗

Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.